MAPK3 and fragile X syndrome: Further to the previous discussion, additional literature evidence suggests that reducing MAPK3 signalling has benefits in alleviating the symptoms and pathophysiology in preclinical models of FXS87–90, which further strengthens the use of Sulindac as a potential treatment for FXS.